Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
March 28 2024 - 3:05PM
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN),
a clinical-stage precision oncology company focused on the
discovery and development of next-generation small molecule kinase
inhibitors, today announced it will host a webcast on Thursday,
April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept
data on ELVN-001 and the evolving chronic myeloid leukemia (CML)
landscape. ELVN-001 is a highly selective, small molecule kinase
inhibitor designed to specifically target the ATP-pocket of the
BCR-ABL gene fusion, the oncogenic driver for patients with CML.
The event will feature leading CML investigators and hematology
care experts, Professor Michael Mauro, M.D., from Memorial Sloan
Kettering Cancer Center, and Professor Fabian Lang, M.D., from
Goethe University Hospital, along with the management of Enliven
Therapeutics. The discussion will cover ELVN-001’s Phase 1a initial
proof of concept data, the evolving treatment paradigm in CML, and
how ELVN-001 could fit into the CML landscape.
The event will be webcast live and can be accessed by visiting
the investor relations section of the Company’s website at
https://ir.enliventherapeutics.com/. To participate in the live
event, please register using this link. An archived webcast will be
available following the event.
About Enliven TherapeuticsEnliven Therapeutics
is a clinical-stage biopharmaceutical company focused on the
discovery and development of small molecule inhibitors to help
people with cancer not only live longer, but live better. Enliven
aims to address existing and emerging unmet needs with a precision
oncology approach that improves survival and enhances overall
well-being. Enliven’s discovery process combines deep insights in
clinically validated biological targets and differentiated
chemistry to design potentially first-in-class or best-in-class
therapies. Enliven is based in Boulder, Colorado.
Contact:Investorsir@enliventherapeutics.com
Mediamedia@enliventherapeutics.com
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From Apr 2024 to May 2024
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From May 2023 to May 2024